Skip to Content

New Drug Approvals Archive - November 2005

November 2005

Exjade (deferasirox) Dispersible Tablets

Date of Approval: November 2, 2005
Company: Novartis
Treatment for: Hemosiderosis, Iron Overload

Exjade (deferasirox) is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions, and non-transfusion-dependent thalassemia.

Read more: Exjade (deferasirox) FDA Approval History

New Drug Approvals Archive